iRhythm Technologies to Report Second Quarter 2024 Financial Results on August 1, 2024

7/18/24 4:05:00 PM ET

Medical/Dental Instruments

Health Care

Get the next $IRTC alert in real time by email

SAN FRANCISCO, July 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2024 after the close of trading on Thursday, August 1, 2024. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com.

About iRhythm Technologies, Inc.

iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all.

Investor Contact

Stephanie Zhadkevich

[email protected]

Media Contact

Kassandra Perry

[email protected]

Get the next $IRTC alert in real time by email

Date	Price Target	Rating	Analyst
12/3/2024	$86.00	Equal Weight	Wells Fargo
10/4/2024	$78.00	Neutral	Goldman
6/20/2024	$115.00	Peer Perform → Outperform	Wolfe Research
12/11/2023	$110.00	Neutral → Buy	Citigroup
7/19/2023	$130.00	Outperform	Robert W. Baird
2/7/2023	$150.00	Overweight	Wells Fargo
11/7/2022		Underperform → Peer Perform	Wolfe Research
6/9/2022	$180.00 → $155.00	Buy → Neutral	Citigroup

iRhythm Technologies to Report Second Quarter 2024 Financial Results on August 1, 2024

Chat with this insight

Recent Analyst Ratings for $IRTC

$IRTC Press Releases

Fastest customizable press release news feed in the world

iRhythm Technologies to Report First Quarter 2025 Financial Results on May 1, 2025

iRhythm Technologies Releases 2024 Corporate Sustainability Report That Demonstrates Ongoing Commitment to Culture of Quality and Sustainability

Turing Medical Names Transformative Med Tech Leader Kevin King as President and Chief Executive Officer

$IRTC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wells Fargo resumed coverage on iRhythm with a new price target

Goldman initiated coverage on iRhythm with a new price target

iRhythm upgraded by Wolfe Research with a new price target

$IRTC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Lawrence Brian Lee

President and CEO Blackford Quentin S. sold $885,932 worth of shares (8,145 units at $108.77), decreasing direct ownership by 4% to 208,741 units (SEC Form 4)

Chief Accounting Officer Rosenbaum Marc W. sold $34,154 worth of shares (314 units at $108.77), decreasing direct ownership by 3% to 11,507 units (SEC Form 4)

$IRTC Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

$IRTC SEC Filings

$IRTC Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$IRTC Financials

Live finance-specific insights

SEC Form DEFA14A filed by iRhythm Technologies Inc.

SEC Form DEF 14A filed by iRhythm Technologies Inc.

SEC Form 10-K filed by iRhythm Technologies Inc.

Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

Chief Commercial Officer Patterson Chad bought $20,994 worth of shares (280 units at $74.98) and sold $224,876 worth of shares (3,012 units at $74.66), decreasing direct ownership by 7% to 37,133 units (SEC Form 4)

Blackford Quentin S. bought $997,644 worth of shares (9,755 units at $102.27), increasing direct ownership by 8% to 128,510 units (SEC Form 4) (Amendment)

iRhythm Technologies to Report First Quarter 2025 Financial Results on May 1, 2025

iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results

iRhythm Technologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

$IRTC Leadership Updates

Live Leadership Updates

iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

Derrick Sung Joins Aerin Medical as Chief Financial Officer

iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments

Recent Analyst Ratings for
$IRTC

$IRTC
Press Releases

$IRTC
Analyst Ratings

$IRTC
Insider Trading

$IRTC
Large Ownership Changes

$IRTC
SEC Filings

$IRTC
Insider Purchases

$IRTC
Financials

$IRTC
Leadership Updates